Partnerships Bioniz Therapeutics (acquired February 2022; exclusive worldwide rights; up to $5M regulatory milestones for EQ302)
Indications
celiac disease(Stage not disclosed)
gastrointestinal diseases(Stage not disclosed)
Status note Bi-specific IL-15/IL-21 inhibitor formulated for oral delivery. IND-enabling development activities initiated.
Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Institutional holders
Fund
Shares
Q/Q change
% of portfolio
Filing
ADAR1 Capital Management
3,758,569
+31,910
0.57%
2026-08-14
Ikarian Capital
303,555
no change
0.16%
2026-08-14
Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.